What defines the point after which a Compounded Sterile Product (CSP) should not be used?

The beyond use date (BUD) is the critical factor that defines the point after which a Compounded Sterile Product (CSP) should not be used. This date is established to ensure the safety and efficacy of the compounded product. The BUD takes into consideration various factors, including the type of CSP, the storage conditions, and the potential for microbial growth after compounding.

BUD is important because it signifies the period during which the product is expected to remain sterile and effective, ensuring patient safety upon administration. It is usually determined by specific guidelines and established protocols to maintain the integrity of the compounded medication.

In contrast, the expiration date primarily pertains to commercially manufactured drugs and signifies the last date a product is guaranteed to maintain its potency and safety when stored under the labeled conditions. The end of shelf life typically refers to the total duration a medication is stable or effective, while the preparation date marks when the CSP was made. Each of these terms serves a different purpose in pharmaceutical practice; however, the beyond use date is the most directly related to the relevant context of when a CSP should no longer be administered.